Atazanavir for the treatment of human immunodeficiency virus infection.
about
Pharmacogenetics as a tool to tailor antiretroviral therapy: A reviewConcentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyNo effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjectsNew drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus.The clinical implications of antiretroviral pharmacogenomics.HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionAtazanavir: its role in HIV treatmentPharmacokinetic optimization of antiretroviral therapy in children and adolescents.Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele.In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.Severe skin rash associated with atazanavir.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes.Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.A Review of Food-Drug Interactions on Oral Drug Absorption.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.The influence of race and comorbidity on the timely initiation of antiretroviral therapy among older persons living with HIV/AIDS.In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agentsPharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamicsAtazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile
P2860
Q26797938-496D946B-F444-4733-9599-4A1CDAFEAF0DQ33776536-9D3EB59F-490F-4F82-89DA-757235EEBF46Q34702576-A0E89CF5-1C56-4E1E-AC15-12785183CF56Q35079510-8532FF8E-95BA-49B6-933C-7819FF68ECF3Q35191614-92859D9D-1CDA-418B-9FB6-31E1F72DF64FQ35595787-986CA173-DCED-44B7-BDAA-9EC62D3D8769Q35941313-A622B43E-3008-4A6B-B578-D6B5FD544B2BQ35967285-851BC660-FE73-4C77-B0B6-EA5D25A718DDQ36497078-681BEB2A-08E7-4957-A78F-3244B89019F0Q36888037-1F277E3E-22E9-41A8-BA8F-C7307885C2CEQ37249418-B856AB44-1694-4E9F-8D0F-E60878AEDF3BQ37835819-2D18030C-EDD6-4DCA-895B-EEB0A9FE97ADQ39429519-2B926F37-4FB9-4BA0-8A18-8BC25269C7CBQ40089973-1D1E3D8D-F8E2-4517-A349-AADA5B81CBAFQ40620508-F445D429-FF5F-447F-9407-FD0736C0036EQ42263920-705DB80A-BA69-4136-995F-8115BEBA0199Q43118505-EF59C7F3-4DB5-4031-AA16-850C17633C63Q43699242-F26681ED-4D7D-4300-91E3-2A2544E1119FQ46384364-8A505510-1869-45EF-B9B8-41F947E105FEQ46525372-A90D5A39-250D-433E-90D1-C4113354E810Q46955645-275F2A18-0085-4C70-A466-2E8119EC078FQ48117745-DCCAEC00-0DB4-4167-98C3-99117110A5A0Q52362144-A5E39BE6-BD76-4B74-8188-18677FA8FACDQ53829397-9EC75DE2-F759-4F24-B3A4-AAE040B9D440Q57109564-F8E0C35A-4E3B-4BA9-91F3-425B925D7E0EQ57403878-A9FE1CB7-9D18-4FE6-A147-AF5A17B9D944Q58291152-7AFFE31C-5C44-49A4-ABAF-052B19CE67E1
P2860
Atazanavir for the treatment of human immunodeficiency virus infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Atazanavir for the treatment of human immunodeficiency virus infection.
@ast
Atazanavir for the treatment of human immunodeficiency virus infection.
@en
type
label
Atazanavir for the treatment of human immunodeficiency virus infection.
@ast
Atazanavir for the treatment of human immunodeficiency virus infection.
@en
prefLabel
Atazanavir for the treatment of human immunodeficiency virus infection.
@ast
Atazanavir for the treatment of human immunodeficiency virus infection.
@en
P2860
P1433
P1476
Atazanavir for the treatment of human immunodeficiency virus infection.
@en
P2093
Anthony J Busti
P2860
P304
P356
10.1592/PHCO.24.17.1732.52347
P407
P577
2004-12-01T00:00:00Z